Nyrada, Inc. · ASX:NYR
Nyrada — Non-Deal Roadshow (August 2020)
18 slides from Nyrada's roadshow presentation, August 2020
Slide 1: Improving Lives, Offering Hope
Improving Lives, Offering Hope New Therapies for Cardiovascular & Neurological Diseases Corporate Presentation July/August 2020 James Bonnar – CEO Prof. Gary Housley – Chair, Scientific Advisory Board ASX:NYR 1
Slide 2: Important Notice & Disclaimer
Important Notice & Disclaimer This presentation has been prepared by Nyrada Inc (NYR or the Company). It should not Although the Company believes that the expectations reflected in the forward looking be considered as an offer or invitation to subscribe for, or purchase any shares in NYR, or stateme
Slide 3: Nyrada Summary
Nyrada Summary Drug discoverer Diverse product portfolio, significant therapeutic and commercial potential, near term milestones. and early stage developer Cholesterol lowering (PCSK9 inhibitors) program to help up to 70% of patients taking statin drugs, a market worth approximately US$19 billion. B
Slide 4: Business Model & Strategy
Business Model & Strategy Innovative Treatments Clinical Need Market Potential Strong Patent Protection First-Line / Best in Class Commercialize Early Cardiovascular Neurology Cholesterol-lowering treatment Brain injury treatment (stroke & head trauma) Value inflection point within 3 years Value inf
Slide 5: Cholesterol and Cardiovascular Disease
Cholesterol and Cardiovascular Disease 1 in 4 Deaths attributed to Cardiovascular Disease • Tobacco use • High blood pressure • High LDL cholesterol Benjamin EJ et al. Heart disease and stroke statistics—2019 update: a report from the American Heart Association. Circulation. 2019 5
Slide 6: Cholesterol Problem (US)
Cholesterol Problem (US) 62.6 million 19.4 million 27.4 million Unable to achieve US adults with elevated Total US adults with LDL-C target despite LDL-C are taking a statin elevated LDL-C taking statin therapy Wong ND et al. Prevalence of the American College of Cardiology/American Heart Associatio
Slide 7: Current Treatment Options
Current Treatment Options Low cost generic statins available Effective, combined with statin US$16 for 100 pills Suboptimal efficacy Expensive US$5,800 per year Side effects Inconvenient US$900M global PCSK9 Inhibitor market in 2019 US$19B global cholesterol-lowering drugs market in 2017 (CAGR 4.9%)
Slide 8: Nyrada Cholesterol-Lowering Solution
Nyrada Cholesterol-Lowering Solution NYX-PSCK9i binds to PCSK9 Blocks action of PCSK9 on cholesterol receptor High PCSK9 = Small molecule PCSK9 inhibitor high LDL cholesterol overcomes longstanding challenge of an oral PCSK9 treatment 8
Slide 9: What is Unique?
What is Unique? Single pill Convenient Cost- treatment for patient effective 9
Slide 10: NYX-PCSK9i Compared to Repatha® and Praluent®
NYX-PCSK9i Compared to Repatha® and Praluent® Nyrada NYX-PCSK9i shows equivalency to Repatha® and Praluent® in human white blood cells Confirmed with/without a statin, supporting NYX-PCSK9i use alone or in combination with statin - Mevastatin + Mevastatin % LDLR retention p-value % LDLR retention p-
Slide 11: Brain Injury Problem
Brain Injury Problem Each year in the US: Neurology / physical rehabilitation only existing - High mortality - 2.8 million people sustain therapies - Severe life-long disability a traumatic brain injury (TBI) - One drug class for stroke - High ongoing healthcare (Suitable for less than 15% of patien
Slide 12: Nyrada Brain Injury Solution
Nyrada Brain Injury Solution Treatment for secondary brain injury following Stroke or TBI - Prevent cell death - Attenuate damaged brain volume - Improve survivability, limit disability, improve quality of life Primary Secondary Disability Injury Injury Level Hours Days Weeks Months 12
Slide 13: Brain Injury Drug Market (US)
Brain Injury Drug Market (US) Hospital admissions each year / patients who present <12hr Traumatic Brain Injury 210,000 (Moderate / Severe) 700,000 patients Annual US market size for brain injury combined (approx.) Stroke 490,000 US$20B global severe TBI treatment market in 2024 (CAGR 5%)1 1 Energia
Slide 14: Preclinical Pharmacokinetic Rat Study
Preclinical Pharmacokinetic Rat Study • Lead drug candidates maintained at therapeutic levels in the brain in PK rat study (intravenous dosing) • Demonstrates delivery via preferred route for patients suffering from stroke and moderate-severe TBI with desired PK profiles for clinical studies 14
Slide 15: Program Status
Program Status First-in-human studies (Phase I) Proof-of-concept Lead optimisation well established advanced - Cholesterol-lowering Drug: late-2021 - Brain Injury Drug: mid-2022 15
Slide 16: Board of Directors
| Board of Directors Mr John Moore Dr Graham Kelly Christopher Cox Mr Peter Marks Mr Marcus Frampton Dr Riidiger Weseloh Non-Executive Non-Executive Non- Executive Non- Executive Non- Executive Non- Executive Chairman Director Director Director Director Director @ Nyrada operates under the direction
Slide 17: Key Metrics & News Flow
Key Metrics & News Flow Market capitalisation H2 H1 H2 H1 $21M 2020 2021 2021 2022 (as at 22 July 2020) Share price Clinical candidate selection for $0.19 cholesterol program: (as at 22 July 2020) Clinical candidate selection for CDIs free float 76,072,869 neuroprotectant program: Cholesterol-loweri
Slide 18: Discover More & Follow Us
Discover More & Follow Us Neuroprotection Cholesterol-Lowering Recent PCSK9i Animation Animation Publication @nyrada_inc @nyrada_inc www.nyrada.com 18